DESIRIAL® PLUS 21mg/ml 1-2ml prefilled syringe

$179.00 /unit

QTY

Brand:

DESIRIAL®

Manufacturer:

Vivacy Laboratories

Active Substance(s):

Hyaluronic Acid and Mannitol

Pack size:

2 pre-filled syringes of 1ml

Packs	For each
1 - 5	$ 179
6 - 10	$ 174
11 - 20	$ 171
21+	$ 169

Worldwide Delivery

Great Customer Service

24/7 Ordering System

Flexible Return Policy

Desirial Plus is a sterile injectable gel made of hyaluronic acid and mannitol. It is commonly used to treat moderate to severe hypotrophy, or atrophy of the vulvar labia majora. At the same time, it is effective against female sexual dysfunction (FSD) associated with the collapse of the G-spot.

Main Benefits

Ingredients

Ingredients Information

Use Instructions

Obtain patient’s free and informed consent before treatment.
Review patient’s medical history with the patient.
Explain indications and expected results to patient. Verify you can fulfill patient’s expectations. Explain contraindications, precautions, potential adverse events, and other important information.
Perform a thorough examination to eliminate the possibility of fungal, viral, or bacterial infection, or vulvo-vaginal inflammation.
Ensure injectable is at room temperature.
Observe current rules for injection asepsis and handling.
Use Lidocaine or another anesthesia if desired for FSD. The manufacturer recommends anesthesia for injection into the labia majora.
Use the cannula or needles supplied with the injectable. Firmly screw needle or cannula onto syringe’s luer lock tip.
Ensure needle has penetrated correctly before injecting.
Inject slowly into the subcutaneous vulvar labia majora or vaginal mucous membrane.
For Female Sexual Dysfunction (FSD), position patient in a gynecological position, with speculum valves positioned laterally. Locate the rough injection area, the G-spot, 2 to 4 cm from the vaginal opening on the vagina’s anterior surface. Inject under the vaginal mucous membrane on either side of the urethra using a 27 G 1/2 needle.
For injection into the vulvar labia majora, inject subcutaneously along longitudinal axis. Use a linear retro-tracing technique, and choose the 18 G cannula.
Do not overcorrect. Inject no more than 20 ml cross-linked hyaluronic acid per person per year.
If patient experiences increased pain during injection, stop injecting and withdraw needle or cannula.
If needle or cannula is blocked, do not increase pressure. Replace the needle or cannula.
Gently massage treated area for optimal correction evenness.
After treatment, properly dispose of syringe, residual product, needles, and cannulas.
Schedule a follow-up consultation a few days after the injection.
Depending on the patient, injection depth, and characteristics of the treated area, you may need to administer a second injection session. Administer follow-up injections regularly to help maintain the desired correction.

Precautions

This is a single-use product. Do not re-use. Use on more than a single patient risks cross-contamination.
Do not resterilize. Inject immediately after opening and discard after injection.
Not for injections other than into subcutaneous vulvar labia majora or vaginal mucous membrane.
Not for injection into clitoral area or labia minora.
Not for injection close to or within the urethra.
Not for use in patients with a tendency to develop hypertrophic scars.
Not for use in patients with a known hypersensitivity to hyaluronic acid, mannitol, or any other ingredient in this injectable.
Not for use in pregnant women.
Not for use in breastfeeding women.
Not for use in children.
Not for use in areas with clinical signs of inflammation or infection, including bacterial, fungal such as thrush, or viral such as papilloma or herpes. Not for use in patients after treatment for one of these infections.
Not for use in blood vessels.
If patient has a history of genital herpes, the needle punctures may trigger a new episode.
Not for injection close to menstruation.
Do not use quaternary ammonium derivatives for disinfection. These could irritate genital mucous membranes.
Not for injection into blood vessels or muscles.
If patient has a history of or currently has autoimmune disease or cancer in an area close to the injection site, decide case-by-case whether to inject, depending on nature of illness and associated treatment. Ensure special monitoring of these patients, including offering a double test before treatment and not injecting if the disease is active.
Perform a double test before treating patients with a history of streptococcal disease including recurrent sore throat or acute rheumatic fever. The manufacturer does not recommend injecting if there is a history of acute rheumatic fever with cardiac localization.
There is no clinical data on injecting this implant into an area corrected by implants of other brands, so the manufacturer does not recommend this.
Do not use if package is open or damaged.
Do not mix with other products.
Do not use cannula if you are treating Female Sexual Dysfunction (FSD).
For injection by legally-authorized practitioners with experience using injection techniques for similar products and with a good anatomical knowledge of treatment site.
In the week before treatment, patient should avoid taking aspirin, NSAIDs, platelet aggregation inhibiting drugs, anticoagulants, or vitamin C.
Patient should notify their doctor if they are undergoing anticoagulant treatment or have a haemostatic disorder, because there is an increased risk of haematomas.
For ten days after injection, patients should avoid going to wet locations, such as swimming pools, gyms, steam rooms, and jacuzzis.
For five days after injection, patient should avoid any sexual activity.
For several days after injection, patient should avoid any activity that puts pressure on the treated area, including cycling and horseback riding.